Testosterone and Growth Hormone for Bone Loss in Men

University of Pennsylvania

Status and phase

Completed

Phase 2

Conditions

Hypogonadism

Growth Hormone Deficiency

Hypopituitarism

Treatments

Drug: testosterone

Drug: Testosterone plus somatropin

Study type

Interventional

Funder types

Other

NIH

Identifiers

NCT00080483

NIAMS-118

R01AR050618 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

Deficiency of testosterone, growth hormone, or both hormones can result in osteoporosis. If either hormone is replaced, the condition of the bones improves. The purpose of this study is to determine if dual hormone treatment for men deficient in testosterone and growth hormone improves bone structure more than testosterone treatment alone.

Full description

Replacement of testosterone or growth hormone in patients who are deficient improves osteoporosis associated with these deficiencies. In some tissues, such as muscle, the effects of testosterone and growth hormone are additive, but it is not known if the effects are additive in bone as well. This study will compare the effects of testosterone alone with testosterone plus growth hormone in improving bone structure in men with total pituitary hormone deficiency.

Participants in this study will be men who have pituitary or hypothalamic disease and have deficiencies of all pituitary hormones, but who have not been treated with either testosterone or growth hormone. The men will be randomly assigned to receive either testosterone alone or testosterone plus growth hormone for two years. Testosterone in a gel form will be applied daily to the skin. Growth hormone will be self-administered by daily subcutaneous injection. Blood concentrations of both hormones will be monitored with blood tests every 3 months during the 2-year study. Doses of the hormones will be adjusted to keep blood concentrations of the hormones within the normal range. Changes in bone structure will be assessed noninvasively before treatment and after one year and two years of treatment by magnetic resonance microimaging (µMRI) and dual energy X-ray absorptiometry (DEXA).

Enrollment

35 patients

Sex

Male

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Documented hypothalamic or pituitary hormone deficiency
Testosterone deficiency, defined as total serum testosterone less than 250 ng/dL at two 8 AM readings
Growth hormone deficiency, defined by either of the following:
For subjects who have thyroxine and cortisol deficiencies, either a subnormal age-specific IGF-1 or a peak GH response to arginine-GHRH of less than 4.1 ng/mL
For subjects who do not have thyroxine and cortisol deficiencies, either a subnormal age-specific IGF-1 or a peak GH response to arginine-GHRH of less than 4.1 ng/mL
Duration of testosterone and growth hormone deficiencies of two years or more
Replacement of cortisol and/or thyroxine deficiencies
Able to give informed consent

Exclusion criteria

Current testosterone treatment or treatment during the two years prior to study entry
Current growth hormone treatment or treatment during the three years prior to study entry
Use of other prescription or over-the-counter androgens (androstenedione, DHEA), estrogens, or antiandrogens (spironolactone, ketoconazole)
Diseases that could influence bone, such as hyperparathyroidism
Medications that could influence bone, such as anticonvulsants or glucocorticoids (prednisone greater than 20 mg/day for longer than 2 weeks/year). Calcium and over-the-counter vitamin D supplements are allowed.
Cancer that could limit life expectancy to fewer than 5 years
Neuromuscular disease or history of stroke with residual neurological defect
Severe or uncontrolled psychiatric illness or dementia
Noncancerous enlargement of the prostate gland (American Urological Association symptom score greater than 21)
Prostate cancer by history, prostate nodule on digital rectal exam (DRE), or prostate specific antigen (PSA) greater than 4
Current alcohol or drug dependence
Heart failure (New York class III or IV)
Unstable angina
Myocardial infarction within 3 months of study entry
Liver disease (ALT greater than 3 x normal)
Renal disease (serum creatinine greater than 2.5 mg/dl)
Diabetes mellitus (glycosolated hemoglobin greater than 8.0%)
Hypertension (systolic BP greater than 160 or diastolic BP greater than 100 mm Hg)
Hematocrit greater than 48%
Weight greater than 300 pounds
Poor quality scan at baseline even when repeated
Untreated, severe, obstructive sleep apnea (Epworth sleepiness score greater than 10)
Unable to undergo an MRI because of a cardiac pacemaker or ferrometallic objects in the body